(Q57188826)

English

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

scientific article published in The Lancet

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

phase II clinical trial

1 reference

based on heuristic

inferred from title

author name string

Juan Pablo Frias

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Michael A Nauck

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Joanna Van

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Mark E Kutner

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Xuewei Cui

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Charles Benson

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Shweta Urva

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Ruth E Gimeno

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Zvonko Milicevic

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Deborah Robins

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Axel Haupt

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

language of work or name

0 references

publication date

4 October 2018

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

392

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

10160

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

2180-2193

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The Physiology of Glucagon-like Peptide 1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Reappraisal of GIP Pharmacology for Metabolic Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin Plays a Permissive Role for the Vasoactive Effect of GIP Regulating Adipose Tissue Metabolism in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

High Visceral Fat Mass and High Liver Fat Are Associated with Resistance to Lifestyle Intervention*

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Central administration of GLP-1 and GIP decreases feeding in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932260-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(18)32260-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30293770%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57188826&oldid=2106412813"